Cladribine vs placebo for non-active progressive multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign informed consent
- You have non-active secondary progressive or relapse-onset secondary progressive multiple sclerosis, not relapsing-remitting or primary progressive
- Your disability has been getting worse over the past 24 months, and you have no relapses in the last 12 months
- Your age is 30 to 65, and you’ve had MS for at least 10 years
- Your disability score (EDSS) is between 3.5 and 7.5
- You can follow strict birth-control rules (and avoid pregnancy) for up to 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether cladribine tablets can help people with stable, long-standing RRMS safely stop their current disease-modifying therapy. It may be an option if your MS has been quiet for years and you want to consider a treatment break.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This study tests whether a donor bone marrow transplant (allogeneic hematopoietic cell transplantation) can stop or slow the progression of primary progressive multiple sclerosis. It is for people with worsening symptoms who have not responded to other treatments.
Hear when a new Multiple Sclerosis, Secondary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.